HC Wainwright Raises HALO Price Target to $130
Key Points
- HC Wainwright reiterated its Buy rating on Halozyme Therapeutics, Inc. and lifted its price target to $130 from $115 on October 8, 2026.
- HC Wainwright's $130 price target implies 7% upside from Halozyme Therapeutics, Inc.'s ($HALO) current $121.49 share price.
- Halozyme Therapeutics recently traded around $121.49 per share as of October 16, 2026, sitting above its closing price of $109.84 on the date of the analyst note.
- Chief Executive Officer Helen I Torley and Director Matthew L Posard completed insider transactions ahead of the analyst update.
Since the rating, $HALO is up 10.6% after 1 week and up 11.5% to date (from the $109.84 close on Oct 8, 2026).
Get Halozyme Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $HALO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Halozyme Therapeutics, Inc. alert may contain errors. Disclosures
HC Wainwright kept its Buy rating on Halozyme Therapeutics, Inc. [HALO] and raised its price target from $115 to $130 on October 8, 2026. The research note outlines a more optimistic outlook for the biopharmaceutical firm as shares trade on the NasdaqGS.
HALO
Halozyme Therapeutics, Inc.
HC Wainwright's Call on Halozyme Therapeutics
On October 8, 2026, HC Wainwright maintained its Buy rating on Halozyme Therapeutics while lifting its price target to $130 from $115. Halozyme closed at $109.84 on the day of the announcement. Other firms also weighed in around the same time, with JP Morgan maintaining a Neutral rating with a $78 target on October 8, 2026, moving from a previous target of $70.
Other Institutional Activity in Halozyme Therapeutics
Boston Partners grew its holdings by 89,903 shares, ending with 2,773,568 shares worth about $339,762,080. William Blair Investment Management, LLC reduced its stake by 14,903 shares, holding 2,511,050 shares valued at roughly $307,603,625.
Halozyme Therapeutics, Inc. Stock Holds Steady
The stock recently traded around $121.49 as of October 16, 2026, which is up about 10.6% since the analyst note when shares closed at $109.84.
$HALO price target
Halozyme Therapeutics, Inc. daily closes and this analyst's $130 target. Not advice.
Recent Earnings
Halozyme generated trailing-twelve-month revenue of $1,663,737,984 with earnings of $3.42 per share. The company reported a net profit margin of 24.9% and a return on equity of 173.7%. Its next financial update is scheduled for release on November 2, 2026.
Insider Buying and Selling at Halozyme Therapeutics, Inc.
Chief Executive Officer Helen I Torley sold 60,000 shares valued at $6,275,592 on August 19, 2026, and another 60,000 shares worth $6,436,711 on September 11, 2026. Director Matthew L Posard sold 18,996 shares for $2,046,581 on September 16, 2026. Later, on October 8, 2026, CEO Helen I Torley sold a further 60,000 shares valued at $6,610,501.
Analysts Set New Price Targets
TD Cowen maintained a Buy rating with a $105 price target on August 7, 2026, moving up from a prior target of $96. Leerink Partners upgraded the stock to an Outperform rating and set a $110 target on August 8, 2026, up from $83. Consensus data points to additional analyst coverage ahead of upcoming corporate milestones.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on proprietary enzymes and delivery devices. Its patented recombinant human hyaluronidase enzyme technology helps deliver injectable biologics and small molecules, supporting pharmaceutical partners worldwide.
Bottom Line
HC Wainwright's higher price target signals growing confidence from the firm as shares trade above previous levels. Investors will look toward the company's upcoming earnings release on November 2, 2026, for further insight into its financial performance.
Related Filing Alerts
Source: HC Wainwright's rating change on $HALO (Oct 8, 2026). Written by software, not financial advice. How we make alerts